dopa

Racemetirosine is an inhibitor of Tyrosine 3-monooxygenase, and consequently it inhibits the synthesis of catecholamines.

L-DOPA methyl ester (LDME) is an agonist of dopamine D1 receptor.

L-DOPA (Levodopa) is an orally active metabolic precursor of the neurotransmitter dopamine. It can cross the blood-brain barrier and be converted into dopamine in the brain. L-DOPA exhibits anti-hyperalgesic effects and holds potential in Parkinson’s disease research, and it can also be used to induce Parkinson’s disease models.

DL-Dopa is a phenylalanine beta-hydroxylated derivative.

Levadopa Related Compound A is the 6-hydroxy derivative of the amino acid L-DOPA with neurotoxic properties. Exogenously administered 6-Hydroxy-L-DOPA is biotransformed by an amino acid decarboxylase to the highly potent and catecholamine-selective neurot

dopamine receptor activator

6-Hydroxy-DOPA is an allosteric inhibitor of RAD52, it inhibits proliferation of BRCA-deficient cancer cells in vitro and also inhibits APE1.

DPBX-L-Dopa is a boron-containing dopa-derivative, acting as a bladder relaxant through non-catecholamine receptors.

3-O-methyl-L-DOPA is a metabolite of L-DOPA , produced by the activity of catechol O-methyltransferase. 3-O-methyl-L-DOPA may have effects of its own or it may compete with the actions of L-DOPA.

D-DOPA is an enantiomer of the dopamine precursor L-DOPA . It can be converted to L-DOPAviasequential oxidation and transamination, which are mediated by D-amino acid oxidase (DAAO) and DOPA transaminase, respectively, in rat kidney homogenates.1It reduces the number of dopaminergic neurons in primary rat embryonic mesencephalic cultures in a concentration-dependent manner.2Intraventricular administration of D-DOPA (200 μg/animal) increases striatal dopamine levels in rats.3D-DOPA (20 mg/kg, i.p.) induces contralateral turns in a rat model of Parkinson's disease induced by 6-OHDA .4 1.Wu, M., Zhou, X.-J., Konno, R., et al.D-dopa is unidirectionally converted to L-dopa by D-amino acid oxidase, followed by dopa transaminaseClin. Exp. Pharmacol. Physiol.33(11)1042-1046(2006) 2.Ling, Z.-D., Pieri, S.C., and Carvey, P.M.Comparison of the neurotoxicity of dihydroxyphenylalanine stereoisomers in cultured dopamine neuronsClin. Neuropharmacol.19(4)360-365(1996) 3.Karoum, F., Freed, W.J., Chuang, L.-W., et al.D-dopa and L-dopa similarly elevate brain dopamine and produce turning behavior in ratsBrain Res.440(1)190-194(1988) 4.Moses, J., Siddiqui, A., and Silverman, P.B.Sodium benzoate differentially blocks circling induced by D-and L-dopa in the hemi-parkinsonian ratNeurosci. Lett.218(3)145-148(1996)

[18F]-Labeled L-dopa precursor is used in the synthesis of 18F-labeled L-dopa[1].

L-DOPA-2,5,6-d3 is a deuterated isotope of L-Dopa for isotope tracing. L-DOPA is an orally active metabolic precursor of the neurotransmitter dopamine, capable of crossing the blood-brain barrier and converting to dopamine within the brain. It exhibits anti-hyperalgesic effects and is utilised in Parkinson's disease research.

Dopamine D2 Receptor Antagonist-1 functions as a negative allosteric modulator (NAM) of the dopamine D2 receptor (D2R), demonstrating sub-millimolar affinity.

Methyldopa (MK-351), an alpha-adrenergic agonist (selective for α2-adrenergic receptors) psychoactive medicine, is served as an antihypertensive or sympatholytic.

Carbidopa monohydrate (S(-)-Carbidopa) is an inhibitor of DOPA decarboxylase, preventing the conversion of levodopa to dopamine.

Methyldopa hydrate (MK-351 hydrate) is a DOPA decarboxylase inhibitor and indirect α2-adrenergic receptor agonist used to treat hypertension. It inhibits the sympathetic nervous system, decreases production of dopamine, norepinephrine, and epinephrine, and exhibits NO-dependent sedative activity.

Oxidopamine hydrobromide (6-OHDA hydrobromide) is a widely used neurotoxin and an antagonist of the neurotransmitter dopamine. It selectively destroys dopaminergic neurons, promotes COX-2 activation, induces PGE2 synthesis, and stimulates the secretion of the pro-inflammatory cytokine IL-1β. It is commonly used to establish animal models of Parkinson’s disease (PD).

Dopamine hydrochloride (ASL279) is a natural catecholamine neurotransmitter that mainly acts on dopamine receptors (D1-5 receptors) (EC50=2.7 nM). Dopamine hydrochloride induces VEGFR2 endocytosis through D2 dopamine receptor and has pro-angiogenic activity.

Carbidopa (Lodosyn) is an aromatic-L-amino-acid decarboxylase inhibitor (IC50: 29±2 μM). It is used in PARKINSON DISEASE to reduce peripheral adverse effects of LEVODOPA.

Compound PDK0318, with CAS No. 645-33-0, is a fragment molecule that serves as an important scaffold for molecular linking, expansion, and modification. Compound PDK0318 provides a structural basis and research tool for the design and screening of novel drug candidates, and is commonly used in drug discovery, drug synthesis, and related research.

Etilevodopa is an ethyl-ester prodrug of Levodopa which is used for the treatment of Parkinson's disease (PD). It is rapidly hydrolyzed to Levodopa and ethanol by nonspecific esterases in the gastrointestinal tract. Levodopa is the direct precursor of dop

L-(-)-α-Methyldopa hydrochloride is an alpha-adrenergic agonist psychoactive drug. It is used as a sympatholytic or antihypertensive. Methyldopa has a dual mechanism of action. It is a competitive inhibitor of the enzyme DOPA decarboxylase, which converts

Etilevodopa hydrochloride (L-DOPA ethyl ester) is a prodrug of levodopa. It also has greater gastric solubility and significant brain penetration.

Levodopa sodium (L-DOPA) is the metabolic precursor of the neurotransmitter dopamine. It is orally active, capable of crossing the blood-brain barrier, and is rapidly taken up by dopaminergic neurons in the brain where it is converted into dopamine. It exhibits anti-hyperalgesic effects and is commonly used to induce animal models of Parkinson's disease.